FGFR3 and breast cancer: Sixty-three percent of patients with NMI-BC are mutant for FGFR3. An additional goal of the present study was to investigate whether adding RAS and PIK3CA mutation analysis to the FGFR3 mutation detection could potentially increase the percentage of patients that can be monitored using urine-based assays for these mutations.